{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:04Z","timestamp":1787020744668,"version":"build-2736575974"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"DOI":"10.1186\/s13027-024-00615-1","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T07:05:02Z","timestamp":1729235102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["From virus to cancer: Epstein\u2013Barr virus miRNA connection in Burkitt's lymphoma"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-2990","authenticated-orcid":false,"given":"Shahram","family":"Jalilian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4858-8723","authenticated-orcid":false,"given":"Mohammad-Navid","family":"Bastani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"issue":"12","key":"615_CR1","doi-asserted-by":"publisher","first-page":"9827","DOI":"10.1128\/JVI.73.12.9827-9831.1999","volume":"73","author":"J Komano","year":"1999","unstructured":"Komano J, Maruo S, Kurozumi K, Oda T, Takada K. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt\u2019s lymphoma cell line Akata. J Virol. 1999;73(12):9827\u201331.","journal-title":"J Virol"},{"issue":"6","key":"615_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.semcancer.2009.07.005","volume":"19","author":"B Gruhne","year":"2009","unstructured":"Gruhne B, Kamranvar SA, Masucci MG, Sompallae R. EBV and genomic instability\u2013a new look at the role of the virus in the pathogenesis of Burkitt\u2019s lymphoma. Semin Cancer Biol. 2009;19(6):394\u2013400.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"615_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.semcancer.2009.07.006","volume":"19","author":"D Vereide","year":"2009","unstructured":"Vereide D, Sugden B. Proof for EBV\u2019s sustaining role in Burkitt\u2019s lymphomas. Semin Cancer Biol. 2009;19(6):389\u201393.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"615_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/CEJ.0000000000000221","volume":"26","author":"Y Wang","year":"2017","unstructured":"Wang Y, Guo Z, Shu Y, Zhou H, Wang H, Zhang W. BART miRNAs: an unimaginable force in the development of nasopharyngeal carcinoma. Eur J Cancer Prev. 2017;26(2):144\u201350.","journal-title":"Eur J Cancer Prev"},{"key":"615_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.virol.2017.09.015","volume":"512","author":"BC Poling","year":"2017","unstructured":"Poling BC, Price AM, Luftig MA, Cullen BR. The Epstein-Barr virus miR-BHRF1 microRNAs regulate viral gene expression in cis. Virology. 2017;512:113\u201323.","journal-title":"Virology"},{"issue":"6","key":"615_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004979","volume":"11","author":"D Kang","year":"2015","unstructured":"Kang D, Skalsky RL, Cullen BR. EBV BART MicroRNAs target multiple pro-apoptotic cellular genes to promote epithelial cell survival. PLoS Pathog. 2015;11(6): e1004979.","journal-title":"PLoS Pathog"},{"issue":"5","key":"615_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/pathogens9050353","volume":"9","author":"S\u017d Lepej","year":"2020","unstructured":"Lepej S\u017d, Matuli\u0107 M, Gr\u0161kovi\u0107 P, Pavlica M, Radmani\u0107 L, Kora\u0107 P. miRNAs: EBV mechanism for escaping host\u2019s immune response and supporting tumorigenesis. Pathogens. 2020;9(5):353. https:\/\/doi.org\/10.3390\/pathogens9050353.","journal-title":"Pathogens"},{"issue":"3","key":"615_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.7150\/ijbs.30099","volume":"15","author":"K Min","year":"2019","unstructured":"Min K, Lee SK. EBV miR-BART10-3p promotes cell proliferation and migration by targeting DKK1. Int J Biol Sci. 2019;15(3):657\u201367.","journal-title":"Int J Biol Sci"},{"issue":"14","key":"615_CR9","doi-asserted-by":"publisher","first-page":"6475","DOI":"10.1128\/JVI.00613-16","volume":"90","author":"JA Verhoeven Rob","year":"2016","unstructured":"Verhoeven Rob JA, Tong S, Zhang G, Zong J, Chen Y, Jin D-Y, et al. NF-\u03baB signaling regulates expression of Epstein-Barr virus BART MicroRNAs and long noncoding RNAs in nasopharyngeal carcinoma. J Virol. 2016;90(14):6475\u201388.","journal-title":"J Virol"},{"issue":"2","key":"615_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.virol.2009.01.006","volume":"386","author":"ZL Pratt","year":"2009","unstructured":"Pratt ZL, Kuzembayeva M, Sengupta S, Sugden B. The microRNAs of Epstein-Barr virus are expressed at dramatically differing levels among cell lines. Virology. 2009;386(2):387\u201397.","journal-title":"Virology"},{"key":"615_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.omtn.2019.07.002","volume":"17","author":"M Wang","year":"2019","unstructured":"Wang M, Gu B, Chen X, Wang Y, Li P, Wang K. The function and therapeutic Potential of Epstein-Barr virus-encoded MicroRNAs in cancer. Molecular Therapy - Nucleic Acids. 2019;17:657\u201368.","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"7","key":"615_CR12","first-page":"1848","volume":"54","author":"M Kawanishi","year":"1996","unstructured":"Kawanishi M. Anti-apoptotic function of the Epstein-Barr virus LMP1 and BHRF1 proteins. Nihon Rinsho. 1996;54(7):1848\u201354.","journal-title":"Nihon Rinsho"},{"issue":"3","key":"615_CR13","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/leu.2015.285","volume":"30","author":"J Ma","year":"2016","unstructured":"Ma J, Nie K, Redmond D, Liu Y, Elemento O, Knowles DM, Tam W. EBV-miR-BHRF1-2 targets PRDM1\/Blimp1: potential role in EBV lymphomagenesis. Leukemia. 2016;30(3):594\u2013604.","journal-title":"Leukemia"},{"issue":"4","key":"615_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01495-21","volume":"96","author":"DN Fachko","year":"2022","unstructured":"Fachko DN, Chen Y, Skalsky RL. Epstein-Barr virus miR-BHRF1-3 targets the BZLF1 3\u2019UTR and regulates the lytic cycle. J Virol. 2022;96(4): e0149521.","journal-title":"J Virol"},{"issue":"8","key":"615_CR15","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.7150\/jca.42498","volume":"11","author":"W Li","year":"2020","unstructured":"Li W, He C, Wu J, Yang D, Yi W. Epstein-Barr virus encodes miRNAs to assist host immune escape. J Cancer. 2020;11(8):2091\u2013100.","journal-title":"J Cancer"},{"issue":"4","key":"615_CR16","doi-asserted-by":"publisher","first-page":"694","DOI":"10.7150\/ijbs.36595","volume":"16","author":"K Min","year":"2020","unstructured":"Min K, Kim JY, Lee SK. Epstein-Barr virus miR-BART1-3p suppresses apoptosis and promotes migration of gastric carcinoma cells by targeting DAB2. Int J Biol Sci. 2020;16(4):694\u2013707.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"615_CR17","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1158\/0008-5472.CAN-07-5126","volume":"68","author":"T Xia","year":"2008","unstructured":"Xia T, O\u2019Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB, et al. EBV MicroRNAs in primary lymphomas and targeting of CXCL-11 by EBV-mir-BHRF1-3. Can Res. 2008;68(5):1436\u201342.","journal-title":"Can Res"},{"issue":"1","key":"615_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-9378-9-12","volume":"9","author":"MR Ambrosio","year":"2014","unstructured":"Ambrosio MR, Navari M, Di Lisio L, Leon EA, Onnis A, Gazaneo S, et al. The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immuno response in Burkitt lymphoma. Infectious Agents Cancer. 2014;9(1):12.","journal-title":"Infectious Agents Cancer"},{"issue":"4","key":"615_CR19","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.3892\/mmr.2017.6173","volume":"15","author":"YM Zhang","year":"2017","unstructured":"Zhang YM, Yu Y, Zhao HP. EBV-BART-6-3p and cellular microRNA-197 compromise the immune defense of host cells in EBV-positive Burkitt lymphoma. Mol Med Rep. 2017;15(4):1877\u201383.","journal-title":"Mol Med Rep"},{"key":"615_CR20","doi-asserted-by":"publisher","first-page":"200276","DOI":"10.1016\/j.tvr.2023.200276","volume":"17","author":"BFR Caetano","year":"2024","unstructured":"Caetano BFR, Rocha VL, Rossini BC, Santos LDD, Oliveira DED. Epstein-Barr Virus miR-BARTs 7 and 9 modulate viral cycle, cell proliferation, and proteomic profiles in Burkitt lymphoma. Tumour Virus Research. 2024;17:200276. https:\/\/doi.org\/10.1016\/j.tvr.2023.200276.","journal-title":"Tumour Virus Research"},{"issue":"1","key":"615_CR21","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41467-022-28479-2","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Ge J, Wang Y, Xiong F, Guo J, Jiang X, et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. Nat Commun. 2022;13(1):866.","journal-title":"Nat Commun"},{"issue":"1","key":"615_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.18632\/oncotarget.4399","volume":"7","author":"PP Piccaluga","year":"2016","unstructured":"Piccaluga PP, Navari M, De Falco G, Ambrosio MR, Lazzi S, Fuligni F, et al. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. Oncotarget. 2016;7(1):224\u201340.","journal-title":"Oncotarget"},{"issue":"5","key":"615_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/rmv.1845","volume":"25","author":"F Valiente-Echeverr\u00eda","year":"2015","unstructured":"Valiente-Echeverr\u00eda F, Hermoso MA, Soto-Rifo R. RNA helicase DDX3: at the crossroad of viral replication and antiviral immunity. Rev Med Virol. 2015;25(5):286\u201399.","journal-title":"Rev Med Virol"},{"key":"615_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad516","author":"J Jin","year":"2023","unstructured":"Jin J, Sun T, Zhang M, Cheng J, Jia Gu, Huang L, Xiao M, Zhou J, Luo H. EBV-encoded MicroRNA-BART17-3p targets DDX3X and promotes EBV infection in EBV-associated T\/natural killer\u2013cell lymphoproliferative diseases. Open Forum Infect Dis. 2023. https:\/\/doi.org\/10.1093\/ofid\/ofad516.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"615_CR25","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/ijc.24655","volume":"126","author":"E Leucci","year":"2010","unstructured":"Leucci E, Onnis A, Cocco M, De Falco G, Imperatore F, Giuseppina A, et al. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. Int J Cancer. 2010;126(6):1316\u201326.","journal-title":"Int J Cancer"},{"issue":"8","key":"615_CR26","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1038\/bcj.2012.29","volume":"2","author":"A Onnis","year":"2012","unstructured":"Onnis A, Navari M, Antonicelli G, Morettini F, Mannucci S, De Falco G, Vigorito E, Leoncini L. Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights into the pathogenesis of Burkitt lymphoma. Blood Cancer J. 2012;2(8):e84\u2013e84. https:\/\/doi.org\/10.1038\/bcj.2012.29.","journal-title":"Blood Cancer J"},{"key":"615_CR27","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.12659\/MSM.897306","volume":"22","author":"L Zhou","year":"2016","unstructured":"Zhou L, Bu Y, Liang Y, Zhang F, Zhang H, Li S. Epstein-Barr Virus (EBV)-BamHI-A rightward transcript (BART)-6 and Cellular MicroRNA-142 synergistically compromise immune defense of host cells in EBV-positive Burkitt lymphoma. Med Sci Monit. 2016;22:4114\u201320.","journal-title":"Med Sci Monit"},{"issue":"6","key":"615_CR28","doi-asserted-by":"publisher","first-page":"e1011970","DOI":"10.1371\/journal.ppat.1011970","volume":"20","author":"Y Chen","year":"2024","unstructured":"Chen Y, Kincaid RP, Bastin K, Fachko DN, Skalsky RL. MicroRNA-focused CRISPR\/Cas9 screen identifies miR-142 as a key regulator of Epstein-Barr virus reactivation. PLoS Pathog. 2024;20(6):e1011970.","journal-title":"PLoS Pathog"},{"issue":"2","key":"615_CR29","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1038\/bcj.2012.1","volume":"2","author":"L Di Lisio","year":"2012","unstructured":"Di Lisio L, S\u00e1nchez-Beato M, G\u00f3mez-L\u00f3pez G, Rodr\u00edguez ME, Montes-Moreno S, Mollejo M, Men\u00e1rguez J, Mart\u00ednez MA, Alves FJ, Pisano DG, Piris MA, Mart\u00ednez N. MicroRNA signatures in B-cell lymphomas. Blood Cancer J. 2012;2(2):e57\u2013e57. https:\/\/doi.org\/10.1038\/bcj.2012.1.","journal-title":"Blood Cancer J"},{"issue":"2","key":"615_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/gcc.20273","volume":"45","author":"J Kluiver","year":"2006","unstructured":"Kluiver J, Haralambieva E, de Jong D, Blokzijl T, Jacobs S, Kroesen BJ, et al. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosom Cancer. 2006;45(2):147\u201353.","journal-title":"Genes Chromosom Cancer"},{"issue":"12","key":"615_CR31","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.3390\/cancers12123546","volume":"12","author":"F Niu","year":"2020","unstructured":"Niu F, Dzikiewicz-Krawczyk A, Koerts J, de Jong D, Wijenberg L, Fernandez Hernandez M, et al. MiR-378a-3p Is critical for Burkitt lymphoma cell growth. Cancers. 2020;12(12):3546.","journal-title":"Cancers"},{"issue":"9","key":"615_CR32","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3390\/v15091808","volume":"15","author":"N Aky\u00fcz","year":"2023","unstructured":"Aky\u00fcz N, Janjetovic S, Ghandili S, Bokemeyer C, Dierlamm J. EBV and 1q gains affect gene and miRNA expression in Burkitt lymphoma. Viruses. 2023;15(9):1808.","journal-title":"Viruses"},{"issue":"9","key":"615_CR33","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1182\/blood-2012-05-402784","volume":"120","author":"L Di Lisio","year":"2012","unstructured":"Di Lisio L, Martinez N, Montes-Moreno S, Piris-Villaespesa M, Sanchez-Beato M, Piris MA. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood. 2012;120(9):1782\u201390.","journal-title":"Blood"},{"key":"615_CR34","doi-asserted-by":"publisher","first-page":"112334","DOI":"10.1016\/j.biopha.2021.112334","volume":"144","author":"F Yazarlou","year":"2021","unstructured":"Yazarlou F, Kadkhoda S, Ghafouri-Fard S. Emerging role of let-7 family in the pathogenesis of hematological malignancies. Biomed Pharmacother. 2021;144:112334.","journal-title":"Biomed Pharmacother"},{"issue":"23","key":"615_CR35","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.1182\/blood-2010-10-315432","volume":"117","author":"MJ Bueno","year":"2011","unstructured":"Bueno MJ, G\u00f3mez M, de Cedr\u00f3n G, G\u00f3mez-L\u00f3pez IP, de Castro L, Lisio Di, Montes-Moreno S, Mart\u00ednez N, Guerrero M, S\u00e1nchez-Mart\u00ednez R, Santos J, Pisano DG, Piris MA, Fern\u00e1ndez-Piqueras J, Malumbres M. Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. Blood. 2011;117(23):6255\u201366. https:\/\/doi.org\/10.1182\/blood-2010-10-315432.","journal-title":"Blood"},{"key":"615_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.omtn.2019.07.002","volume":"17","author":"M Wang","year":"2019","unstructured":"Wang M, Gu B, Chen X, Wang Y, Li P, Wang K. The function and therapeutic potential of Epstein-Barr virus-encoded microRNAs in cancer. Molecular Therapy-Nucleic Acids. 2019;17:657\u201368.","journal-title":"Molecular Therapy-Nucleic Acids"},{"issue":"1","key":"615_CR37","doi-asserted-by":"publisher","first-page":"224","DOI":"10.18632\/oncotarget.4399","volume":"7","author":"PP Piccaluga","year":"2015","unstructured":"Piccaluga PP, Navari M, De Falco G, Ambrosio MR, Lazzi S, Fuligni F, et al. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. Oncotarget. 2015;7(1):224\u201340. https:\/\/doi.org\/10.18632\/oncotarget.4399.","journal-title":"Oncotarget"},{"key":"615_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.935205","volume":"12","author":"T Yang","year":"2022","unstructured":"Yang T, You C, Meng S, Lai Z, Ai W, Zhang J. EBV infection and its regulated metabolic reprogramming in nasopharyngeal tumorigenesis. Front Cell Infect Microbiol. 2022;12: 935205.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"615_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13027-020-00292-w","volume":"15","author":"M Granai","year":"2020","unstructured":"Granai M, Mundo L, Akarca AU, Siciliano MC, Rizvi H, Mancini V, et al. Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and noncanonical EBV latency program. Infectious Agents and Cancer. 2020;15(1):28.","journal-title":"Infectious Agents and Cancer"},{"key":"615_CR40","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fmicb.2017.00501","volume":"8","author":"CI Oduor","year":"2017","unstructured":"Oduor CI, Movassagh M, Kaymaz Y, Chelimo K, Otieno J, Ong\u2019echa JM, et al. Human and Epstein-Barr Virus miRNA Profiling as predictive biomarkers for endemic Burkitt lymphoma. Front Microbiol. 2017;8:501.","journal-title":"Front Microbiol"},{"issue":"4","key":"615_CR41","doi-asserted-by":"publisher","first-page":"166049","DOI":"10.1016\/j.bbadis.2020.166049","volume":"1867","author":"K Torres","year":"2021","unstructured":"Torres K, Landeros N, Wichmann IA, Polakovicova I, Aguayo F, Corvalan AH. EBV miR-BARTs and human lncRNAs: shifting the balance in competing endogenous RNA networks in EBV-associated gastric cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2021;1867(4):166049. https:\/\/doi.org\/10.1016\/j.bbadis.2020.166049.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"issue":"2","key":"615_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.26444\/jpccr\/138306","volume":"15","author":"M Kolesnik","year":"2021","unstructured":"Kolesnik M, Stepien E, Polz-Dacewicz M. The role of microRNA (miRNA) as a biomarker in HPV and EBV-related cancers. J Pre-Clin Clin Res. 2021;15(2):104\u201310.","journal-title":"J Pre-Clin Clin Res"},{"issue":"2","key":"615_CR43","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s11033-021-06152-z","volume":"48","author":"S Soltani","year":"2021","unstructured":"Soltani S, Zakeri A, Tabibzadeh A, Zakeri AM, Zandi M, Siavoshi S, et al. A review on EBV encoded and EBV-induced host microRNAs expression profile in different lymphoma types. Mol Biol Rep. 2021;48(2):1801\u201317.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"615_CR44","doi-asserted-by":"publisher","first-page":"565","DOI":"10.7150\/ijbs.24562","volume":"14","author":"M Wang","year":"2018","unstructured":"Wang M, Yu F, Wu W, Wang Y, Ding H, Qian L. Epstein-Barr virus-encoded microRNAs as regulators in host immune responses. Int J Biol Sci. 2018;14(5):565\u201376.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"615_CR45","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/ijms19041168","volume":"19","author":"M Navari","year":"2018","unstructured":"Navari M, Etebari M, Ibrahimi M, Leoncini L, Piccaluga P. Pathobiologic roles of Epstein\u2013barr virus-encoded micrornas in human lymphomas. Int J Mol Sci. 2018;19(4):1168. https:\/\/doi.org\/10.3390\/ijms19041168.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"615_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13027-020-00307-6","volume":"15","author":"V De Re","year":"2020","unstructured":"De Re V, Caggiari L, De Zorzi M, Fanotto V, Miolo G, Puglisi F, et al. Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer. Infectious Agents and Cancer. 2020;15(1):42.","journal-title":"Infectious Agents and Cancer"},{"issue":"6","key":"615_CR47","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.semcancer.2009.07.003","volume":"19","author":"G De Falco","year":"2009","unstructured":"De Falco G, Antonicelli G, Onnis A, Lazzi S, Bellan C, Leoncini L. Role of EBV in microRNA dysregulation in Burkitt lymphoma. Semin Cancer Biol. 2009;19(6):401\u20136.","journal-title":"Semin Cancer Biol"},{"key":"615_CR48","doi-asserted-by":"crossref","unstructured":"Iwakiri D, Takada K. Chapter 4 - Role of EBERs in the Pathogenesis of EBV Infection. In: Vande Woude GF, Klein G, editors. Advances in Cancer Research. 107: Academic Press; 2010. p. 119-36","DOI":"10.1016\/S0065-230X(10)07004-1"},{"issue":"3","key":"615_CR49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12250-017-3996-5","volume":"32","author":"L Zuo","year":"2017","unstructured":"Zuo L, Yue W, Du S, Xin S, Zhang J, Liu L, et al. An update: Epstein-Barr virus and immune evasion via microRNA regulation. Virologica Sinica. 2017;32(3):175\u201387.","journal-title":"Virologica Sinica"},{"issue":"5","key":"615_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009217","volume":"17","author":"N Ungerleider","year":"2021","unstructured":"Ungerleider N, Bullard W, Kara M, Wang X, Roberts C, Renne R, et al. EBV miRNAs are potent effectors of tumor cell transcriptome remodeling in promoting immune escape. PLoS Pathog. 2021;17(5): e1009217.","journal-title":"PLoS Pathog"},{"issue":"11\u201312","key":"615_CR51","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.bbagrm.2011.06.012","volume":"1809","author":"IW Boss","year":"2011","unstructured":"Boss IW, Renne R. Viral miRNAs and immune evasion. Biochim Biophys Acta. 2011;1809(11\u201312):708\u201314.","journal-title":"Biochim Biophys Acta"},{"key":"615_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/516047","volume":"2010","author":"JM God","year":"2010","unstructured":"God JM, Haque A. Burkitt lymphoma: pathogenesis and immune evasion. J Oncol. 2010;2010:1\u201314. https:\/\/doi.org\/10.1155\/2010\/516047.","journal-title":"J Oncol"},{"issue":"1","key":"615_CR53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12929-023-00964-w","volume":"30","author":"HM Nail","year":"2023","unstructured":"Nail HM, Chiu CC, Leung CH, Ahmed MMM, Wang HD. Exosomal miRNA-mediated intercellular communications and immunomodulatory effects in tumor microenvironments. J Biomed Sci. 2023;30(1):69.","journal-title":"J Biomed Sci"},{"key":"615_CR54","doi-asserted-by":"publisher","first-page":"1289313","DOI":"10.3389\/fimmu.2023.1289313","volume":"14","author":"DG Sausen","year":"2023","unstructured":"Sausen DG, Poirier MC, Spiers LM, Smith EN. Mechanisms of T-cell evasion by Epstein-Barr virus and implications for tumor survival. Front Immunol. 2023;14:1289313.","journal-title":"Front Immunol"},{"issue":"1","key":"615_CR55","doi-asserted-by":"publisher","first-page":"14786","DOI":"10.1038\/s41598-020-71775-4","volume":"10","author":"F Ghasemi","year":"2020","unstructured":"Ghasemi F, Tessier TM, Gameiro SF, Maciver AH, Cecchini MJ, Mymryk JS. High MHC-II expression in Epstein-Barr virus-associated gastric cancers suggests that tumor cells serve an important role in antigen presentation. Sci Rep. 2020;10(1):14786.","journal-title":"Sci Rep"},{"issue":"20","key":"615_CR56","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.3390\/cancers13205189","volume":"13","author":"M Bauer","year":"2021","unstructured":"Bauer M, Jasinski-Bergner S, Mandelboim O, Wickenhauser C, Seliger B. Epstein-Barr virus\u2014associated malignancies and immune escape: the role of the tumor microenvironment and tumor cell evasion strategies. Cancers. 2021;13(20):5189.","journal-title":"Cancers"},{"key":"615_CR57","doi-asserted-by":"publisher","first-page":"807895","DOI":"10.3389\/fimmu.2021.807895","volume":"12","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Huang Q, Yu L, Zhu D, Li Y, Xue Z, et al. The role of miRNA in tumor immune escape and miRNA-based therapeutic strategies. Front Immunol. 2022;12:807895.","journal-title":"Front Immunol"},{"issue":"2","key":"615_CR58","doi-asserted-by":"publisher","first-page":"03440","DOI":"10.1128\/mBio.03440-20","volume":"12","author":"M Bouvet","year":"2021","unstructured":"Bouvet M, Voigt S, Tagawa T, Albanese M, Chen Y-FA, Chen Y, et al. Multiple viral microRNAs regulate interferon release and signaling early during infection with Epstein-Barr virus. MBio. 2021;12(2):03440.","journal-title":"MBio"},{"issue":"2","key":"615_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JVI.00530-17","volume":"91","author":"CM Skinner","year":"2017","unstructured":"Skinner CM, Ivanov NS, Barr SA, Chen Y, Skalsky RL. An Epstein-barr virus microRNA blocks interleukin-1 (il-1) signaling by targeting il-1 receptor 1. J Virol. 2017;91(2):10. https:\/\/doi.org\/10.1128\/JVI.00530-17.","journal-title":"J Virol"},{"issue":"1","key":"615_CR60","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.jcvp.2023.100171","volume":"4","author":"J Hassan","year":"2024","unstructured":"Hassan J, Gonzalez G, Stack M, Dolan N, Sweeney C, De Gascun C, et al. Longitudinal analysis of the impact of rituximab on circulating EBV miRNAs in three pediatric kidney transplant recipients. J Clinical Virol Plus. 2024;4(1):100171.","journal-title":"J Clinical Virol Plus"},{"issue":"25","key":"615_CR61","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood.2019000889","volume":"134","author":"AS Cristino","year":"2019","unstructured":"Cristino AS, Nourse J, West RA, Sabdia MB, Law SC, Gunawardana J, et al. EBV microRNA-BHRF1-2-5p targets the 3\u2019UTR of immune checkpoint ligands PD-L1 and PD-L2. Blood. 2019;134(25):2261\u201370.","journal-title":"Blood"},{"key":"615_CR62","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fimmu.2018.00433","volume":"9","author":"AR Naqvi","year":"2018","unstructured":"Naqvi AR, Shango J, Seal A, Shukla D, Nares S. Viral miRNAs alter host cell miRNA profiles and modulate innate immune responses. Front Immunol. 2018;9:433.","journal-title":"Front Immunol"},{"key":"615_CR63","unstructured":"Ying C, Hui J, Peng X, Huang Y, Yan X, Zhu B, editors. Plasma EBV miRNAs Profiles Reveal Potential Biomarkers for clinical prognosis of Acquired Immune Deficiency Syndrome-related Lymphoma2020."},{"issue":"1","key":"615_CR64","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1566524023666221118122005","volume":"24","author":"WT Wang","year":"2024","unstructured":"Wang WT, Yang Y, Zhang Y, Le YN, Wu YL, Liu YY, Tu YJ. EBV-microRNAs as potential biomarkers in EBV-related fever: a narrative review. Curr Mol Med. 2024;24(1):2\u201313.","journal-title":"Curr Mol Med"},{"issue":"7","key":"615_CR65","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/cas.12156","volume":"104","author":"S Chen","year":"2013","unstructured":"Chen S, Wang Z, Dai X, Pan J, Ge J, Han X, et al. Re-expression of microRNA-150 induces EBV-positive Burkitt lymphoma differentiation by modulating c-Myb in vitro. Cancer Sci. 2013;104(7):826\u201334.","journal-title":"Cancer Sci"},{"issue":"1","key":"615_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbcan.2011.09.001","volume":"1825","author":"M-L He","year":"2012","unstructured":"He M-L, Luo M-M, Lin MC, Kung H-f. MicroRNAs: potential diagnostic markers and therapeutic targets for EBV-associated nasopharyngeal carcinoma. Biochimica et Biophys Acta (BBA) - Rev Cancer. 2012;1825(1):1\u201310. https:\/\/doi.org\/10.1016\/j.bbcan.2011.09.001.","journal-title":"Biochimica et Biophys Acta (BBA) - Rev Cancer"},{"issue":"13","key":"615_CR67","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.3390\/ijms23137265","volume":"23","author":"Z Wy\u017cewski","year":"2022","unstructured":"Wy\u017cewski Z, Mielcarska MB, Gregorczyk-Zboroch KP, Myszka A. Virus-mediated inhibition of apoptosis in the context of EBV-associated diseases: molecular mechanisms and therapeutic perspectives. Int J Mol Sci. 2022;23(13):7265.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"615_CR68","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clml.2012.11.003","volume":"13","author":"D Olson","year":"2013","unstructured":"Olson D, Gulley ML, Tang W, Wokocha C, Mechanic O, Hosseinipour M, et al. Phase I clinical trial of Valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi. Clin Lymphoma Myeloma Leuk. 2013;13(2):112\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"615_CR69","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","volume":"55","author":"T Kim","year":"2023","unstructured":"Kim T, Croce CM. MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies. Exp Mol Med. 2023;55(7):1314\u201321.","journal-title":"Exp Mol Med"},{"issue":"1","key":"615_CR70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41544-019-0024-y","volume":"1","author":"Y Fu","year":"2019","unstructured":"Fu Y, Chen J, Huang Z. Recent progress in microRNA-based delivery systems for the treatment of human disease. ExRNA. 2019;1(1):24.","journal-title":"ExRNA"},{"key":"615_CR71","doi-asserted-by":"publisher","first-page":"526455","DOI":"10.3389\/fpls.2020.526455","volume":"11","author":"J Neumeier","year":"2021","unstructured":"Neumeier J, Meister G. siRNA specificity: RNAi mechanisms and strategies to reduce off-target effects. Front Plant Sci. 2021;11:526455. https:\/\/doi.org\/10.3389\/fpls.2020.526455.","journal-title":"Front Plant Sci"},{"issue":"2","key":"615_CR72","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/nar\/gku1343","volume":"43","author":"ST Sarvestani","year":"2015","unstructured":"Sarvestani ST, Stunden HJ, Behlke MA, Forster SC, McCoy CE, Tate MD, et al. Sequence-dependent off-target inhibition of TLR7\/8 sensing by synthetic microRNA inhibitors. Nucleic Acids Res. 2015;43(2):1177\u201388.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"615_CR73","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/v8060156","volume":"8","author":"D Piedade","year":"2016","unstructured":"Piedade D, Azevedo-Pereira JM. The role of microRNAs in the pathogenesis of herpesvirus infection. Viruses. 2016;8(6):156.","journal-title":"Viruses"},{"issue":"6","key":"615_CR74","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/biom13060877","volume":"13","author":"H Yang","year":"2023","unstructured":"Yang H, Liu Y, Chen L, Zhao J, Guo M, Zhao X, et al. MiRNA-based therapies for lung cancer: opportunities and challenges? Biomolecules. 2023;13(6):877.","journal-title":"Biomolecules"},{"issue":"12","key":"615_CR75","first-page":"812","volume":"16","author":"JP Gastwirt","year":"2018","unstructured":"Gastwirt JP, Roschewski M. Management of adults with Burkitt lymphoma. Clin Adv Hematol Oncol. 2018;16(12):812\u201322.","journal-title":"Clin Adv Hematol Oncol"},{"key":"615_CR76","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.2147\/IDR.S375624","volume":"16","author":"O Andersen","year":"2023","unstructured":"Andersen O, Ernberg I, Hedstr\u00f6m AK. Treatment options for Epstein-Barr virus-related disorders of the central nervous system. infect Drug Resist. 2023;16:4599\u2013620.","journal-title":"infect Drug Resist"},{"issue":"1","key":"615_CR77","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-022-00404-3","volume":"8","author":"C L\u00f3pez","year":"2022","unstructured":"L\u00f3pez C, Burkhardt B, Chan JK, Leoncini L, Mbulaiteye SM, Ogwang MD, et al. Burkitt lymphoma. Nat Rev Dis Primers. 2022;8(1):78.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"615_CR78","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/cancers10060197","volume":"10","author":"JS Pagano","year":"2018","unstructured":"Pagano JS, Whitehurst CB, Andrei G. Antiviral drugs for EBV. Cancers. 2018;10(6):197.","journal-title":"Cancers"},{"key":"615_CR79","doi-asserted-by":"publisher","first-page":"798008","DOI":"10.3389\/fonc.2021.798008","volume":"11","author":"C Wang","year":"2022","unstructured":"Wang C, Liu J, Liu Y. Progress in the treatment of HIV-associated lymphoma when combined with the antiretroviral therapies. Front Oncol. 2022;11:798008. https:\/\/doi.org\/10.3389\/fonc.2021.798008.","journal-title":"Front Oncol"},{"issue":"3","key":"615_CR80","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1080\/10428194.2022.2027402","volume":"64","author":"JY Tan","year":"2023","unstructured":"Tan JY, Qiu TY, Chiang J, Tan YH, Yang VS, Chang EWY, et al. Burkitt lymphoma \u2013 no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy. Leuk Lymphoma. 2023;64(3):586\u201396.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"615_CR81","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/jha2.624","volume":"4","author":"C Wang","year":"2023","unstructured":"Wang C, Liang S, Quan X, Guo B, Huang D, Li J, Liu Y. HIV-associated Burkitt lymphoma in the combination antiretroviral therapy era: real-world outcomes and prognostication. EJHaem. 2023;4(1):100\u20137.","journal-title":"EJHaem"},{"issue":"3","key":"615_CR82","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1089\/apc.2007.0124","volume":"22","author":"VS Blinder","year":"2008","unstructured":"Blinder VS, Chadburn A, Furman RR, Mathew S, Leonard JP. Review: improving outcomes for patients with Burkitt lymphoma and HIV. AIDS Patient Care STDS. 2008;22(3):175\u201387.","journal-title":"AIDS Patient Care STDS"},{"issue":"52","key":"615_CR83","doi-asserted-by":"publisher","first-page":"e23853","DOI":"10.1097\/MD.0000000000023853","volume":"99","author":"V Birlutiu","year":"2020","unstructured":"Birlutiu V, Birlutiu R-M, Zaharie IS, Sandu M. Burkitt lymphoma associated with human immunodeficiency virus infection and pulmonary tuberculosis: a case report. Medicine. 2020;99(52):e23853. https:\/\/doi.org\/10.1097\/MD.0000000000023853.","journal-title":"Medicine"},{"issue":"14","key":"615_CR84","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","volume":"119","author":"K Dunleavy","year":"2012","unstructured":"Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012;119(14):3245\u201355.","journal-title":"Blood"},{"issue":"33","key":"615_CR85","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1038\/sj.onc.1206548","volume":"22","author":"BF Israel","year":"2003","unstructured":"Israel BF, Kenney SC. Virally targeted therapies for EBV-associated malignancies. Oncogene. 2003;22(33):5122\u201330.","journal-title":"Oncogene"},{"issue":"7","key":"615_CR86","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/cas.13634","volume":"109","author":"H Li","year":"2018","unstructured":"Li H, Hu J, Luo X, Bode AM, Dong Z, Cao Y. Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies. Cancer Sci. 2018;109(7):2101\u20138.","journal-title":"Cancer Sci"},{"issue":"7","key":"615_CR87","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2174\/156800908786241069","volume":"8","author":"P De Paoli","year":"2008","unstructured":"De Paoli P. Novel virally targeted therapies of EBV-associated tumors. Curr Cancer Drug Targets. 2008;8(7):591\u20136.","journal-title":"Curr Cancer Drug Targets"},{"issue":"16","key":"615_CR88","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.3390\/cancers13164079","volume":"13","author":"JM Knerr","year":"2021","unstructured":"Knerr JM, Kledal TN, Rosenkilde MM. Molecular properties and therapeutic targeting of the EBV-encoded receptor BILF1. Cancers. 2021;13(16):4079.","journal-title":"Cancers"},{"issue":"1","key":"615_CR89","first-page":"3","volume":"57","author":"A Sato","year":"2016","unstructured":"Sato A, Yamakawa N, Kotani A. Pathogenesis and novel therapy for EBV-related B-cell lymphoma. Rinsho Ketsueki. 2016;57(1):3\u20138.","journal-title":"Rinsho Ketsueki"},{"key":"615_CR90","first-page":"55","volume":"117","author":"S Kenney","year":"2006","unstructured":"Kenney S, Theodore E. Woodward award: development of novel, EBV-targeted therapies for EBV-positive tumors. Trans Am Clin Climatol Assoc. 2006;117:55\u201373.","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"615_CR91","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13027-020-00307-6","volume":"15","author":"V De Re","year":"2020","unstructured":"De Re V, Caggiari L, De Zorzi M, Fanotto V, Miolo G, Puglisi F, et al. Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer. Infect Agent Cancer. 2020;15:42.","journal-title":"Infect Agent Cancer"},{"key":"615_CR92","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.omtn.2019.07.002","volume":"17","author":"M Wang","year":"2019","unstructured":"Wang M, Gu B, Chen X, Wang Y, Li P, Wang K. The function and therapeutic potential of Epstein-barr virus-encoded micrornas in cancer. Mol Ther Nucleic Acids. 2019;17:657\u201368.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"615_CR93","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mSphere.00093-21","volume":"6","author":"Y Chen","year":"2021","unstructured":"Chen Y, Fachko DN, Ivanov NS, Skalsky RL. B-cell receptor-responsive miR-141 enhances Epstein-Barr virus lytic cycle via FOXO3 Inhibition. mSphere. 2021;6(2):10.","journal-title":"mSphere."},{"issue":"2","key":"615_CR94","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4143\/crt.2019.457","volume":"52","author":"DM Xu","year":"2020","unstructured":"Xu DM, Kong YL, Wang L, Zhu HY, Wu JZ, Xia Y, et al. EBV-miR-BHRF1-1 targets p53 gene: potential role in Epstein-Barr virus associated chronic lymphocytic leukemia. Cancer Res Treat. 2020;52(2):492\u2013504.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"615_CR95","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1158\/0008-5472.CAN-07-5126","volume":"68","author":"T Xia","year":"2008","unstructured":"Xia T, O\u2019Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB, et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by EBV-mir-BHRF1-3. Cancer Res. 2008;68(5):1436\u201342.","journal-title":"Cancer Res"},{"issue":"1","key":"615_CR96","doi-asserted-by":"publisher","first-page":"224","DOI":"10.18632\/oncotarget.4399","volume":"7","author":"PP Piccaluga","year":"2015","unstructured":"Piccaluga PP, Navari M, Falco GD, Ambrosio MR, Lazzi S, Fuligni F, et al. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. Oncotarget. 2015;7(1):224.","journal-title":"Oncotarget"},{"issue":"1","key":"615_CR97","first-page":"89","volume":"13","author":"B Han","year":"2020","unstructured":"Han B, Wang S, Zhao H. MicroRNA-21 and microRNA-155 promote the progression of Burkitt\u2019s lymphoma by the PI3K\/AKT signaling pathway. Int J Clin Exp Pathol. 2020;13(1):89\u201398.","journal-title":"Int J Clin Exp Pathol"},{"issue":"9","key":"615_CR98","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3390\/genes12091302","volume":"12","author":"BR Ramorola","year":"2021","unstructured":"Ramorola BR, Goolam-Hoosen T, de Souza A, Rios L, Mowla S. Modulation of cellular MicroRNA by HIV-1 in Burkitt lymphoma cells\u2014a pathway to promoting oncogenesis. Genes. 2021;12(9):1302.","journal-title":"Genes"},{"key":"615_CR99","doi-asserted-by":"publisher","first-page":"629780","DOI":"10.3389\/fonc.2021.629780","volume":"11","author":"MML Leong","year":"2021","unstructured":"Leong MML, Lung ML. The impact of Epstein-barr virus infection on epigenetic regulation of host cell gene expression in epithelial and lymphocytic malignancies. Front Oncol. 2021;11:629780.","journal-title":"Front Oncol"},{"key":"615_CR100","doi-asserted-by":"publisher","first-page":"1342455","DOI":"10.3389\/fimmu.2024.1342455","volume":"15","author":"IY Kong","year":"2024","unstructured":"Kong IY, Giulino-Roth L. Targeting latent viral infection in EBV-associated lymphomas. Front Immunol. 2024;15:1342455.","journal-title":"Front Immunol"},{"issue":"12","key":"615_CR101","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1166\/jbt.2020.2518","volume":"10","author":"G Ye","year":"2020","unstructured":"Ye G, He S, Pan R, Zhu L, Zhou D, Lu R. miR-34a reverses doxorubicin resistance in breast cancer. J Biomater Tissue Eng. 2020;10(12):1820\u20136.","journal-title":"J Biomater Tissue Eng"},{"issue":"12","key":"615_CR102","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1038\/s41379-020-0575-3","volume":"33","author":"L Mundo","year":"2020","unstructured":"Mundo L, Del Porro L, Granai M, Siciliano MC, Mancini V, Santi R, et al. Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas. Mod Pathol. 2020;33(12):2407\u201321.","journal-title":"Mod Pathol"},{"issue":"1","key":"615_CR103","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mBio.01941-18","volume":"10","author":"A Murer","year":"2019","unstructured":"Murer A, R\u00fchl J, Zbinden A, Capaul R, Hammerschmidt W, Chijioke O, M\u00fcnz C. MicroRNAs of Epstein-Barr virus attenuate T-cell-mediated immune control in vivo. MBio. 2019;10(1):10.","journal-title":"MBio"}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-024-00615-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-024-00615-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-024-00615-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T18:02:19Z","timestamp":1729274539000},"score":1,"resource":{"primary":{"URL":"https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-024-00615-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1186\/s13027-024-00615-1","relation":{},"ISSN":["1750-9378"],"issn-type":[{"value":"1750-9378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"4 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential Competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}